QIAGEN Awarded 2007 Workplace Excellence Award
Latest award in a series of national and international recognitions for QIAGEN as employer of talented, passionate and motivated employees
GERMANTOWN, MD - June 13, 2007 - QIAGEN (NASDAQ: QGEN), the worldwide leading provider of sample and assay technologies for life sciences, applied testing and molecular diagnostics, has been awarded the 2007 Workplace Excellence Award from the Alliance for Workplace Excellence.
According to the Alliance, the award recognizes visionary employers who are paving the way to a workplace where men and women are able to experience professional and personal fulfillment and success, not only at work, but also at home and within the community.
"We are honored to receive this award," said Peer Schatz, QIAGEN's CEO. "At QIAGEN, we significantly invest to continue to improve our position as an excellent and high performance employer and organization. One key factor contributing to our position is our employees' experience working in a highly focused company at the forefront of scientific research and healthcare, where their contributions to have a real, measurable and important impact on building a better world."
In order to receive the award, QIAGEN completed a comprehensive and rigorous assessment process led by an independent review panel. The company demonstrated exemplary commitment to Supportive Corporate Culture and Management Practices; Family and Employee Friendly Policies and Practices; Strong Employee Health and Wellness Initiatives; Comprehensive Growth and Learning Opportunities; and Demonstration to Corporate Social Responsibility and Employee Volunteerism.
"An ideal or winning workplace means providing meaningful opportunities to employees for growth and development while continuing to grow the business and expanding our competitive position in the marketplace," said Douglas Liu, Global VP Operations and Chairman of QIAGEN's North American Leadership Team (NALT).
This award is the latest award in a series of national and international recognitions for QIAGEN's position as an employer of talented, passionate and motivated employees. For example, in April 2007 "The Scientist", one of the world's leading magazines for the Life Sciences recognized the Company as one of the best places to work for in Life Sciences. In March 2007, QIAGEN was recognized by the Corporate Research Foundation (CRF) and Geva Institut in Munich as one of Germany's "Best Companies to Work For".
QIAGEN will receive the award June 14 at the North Bethesda (MD) Marriott Hotel and Convention Center.
QIAGEN Inc., with US headquarters in Germantown, MD, is the worldwide leading provider of sample and assay technologies for research in life sciences, applied testing and molecular diagnostics. QIAGEN has developed a comprehensive portfolio of more than 500 proprietary, consumable products and automated solutions for sample collection, nucleic acid and protein handling, separation, and purification, as well as target specific detection reagents used in laboratory-developed tests. The company's products are sold to academic research markets, leading pharmaceutical and biotechnology companies, applied testing customers (e.g., forensics, veterinary, biodefense and industrial applications) as well as to molecular diagnostics laboratories. QIAGEN employs more than 1,950 people worldwide. Its North American operations are responsible for over 40% of the company's revenues. The 200,000 square foot headquarters facility is home to R&D, Marketing and Sales, as well as a state-of-the-art manufacturing facility focused on buffer production and filling, device assembly, protein crystallization, siRNA liquid handling, and assembly. QIAGEN products are sold through a dedicated sales force and a global network of distributors in more than 40 countries. Further information about QIAGEN can be found at http://www.qiagen.com/.
Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, markets, strategy or operating results are forward-looking, such statements are based on current expectations that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations and risks of dependency on logistics), variability of operating results, the commercial development of the applied testing markets, clinical research markets and proteomics markets, nucleic acid-based molecular diagnostics market, and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for QIAGEN's, products (including fluctuations due to the level and timing of customers' funding, budgets, and other factors), our ability to obtain regulatory approval of our infectious disease panels, difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products, the ability of QIAGEN to identify and develop new products and to differentiate its products from competitors' products, market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses. For further information, refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).
Nicole A. York